Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5559111 | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5559111 (Pediatric) | NODEN PHARMA | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan, 2019
(5 years ago) | |
US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(1 year, 9 months from now) | |
US8617595 (Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(2 years from now) |
Tekturna is owned by Noden Pharma.
Tekturna contains Aliskiren Hemifumarate.
Tekturna has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tekturna are:
Tekturna was authorised for market use on 05 March, 2007.
Tekturna is available in tablet;oral dosage forms.
Tekturna can be used as treatment of hypertension.
Drug patent challenges can be filed against Tekturna from 06 March, 2011.
The generics of Tekturna are possible to be released after 19 August, 2026.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 05 March, 2007
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL